Publications

  1. Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun; 19 (6):928-940 Epub 2024 Jan 24
    View PubMed
  2. Mitchell MI, Ben-Dov IZ, Ye K, Liu C, Shi M, Sadoughi A, Shah C, Siddiqui T, Okorozo A, Gutierrez M, Unawane R, Biamonte L, Parikh K, Spivack S, Loudig O. Exhaled breath condensate contains extracellular vesicles (EVs) that carry miRNA cargos of lung tissue origin that can be selectively purified and analyzed. J Extracell Vesicles. 2024 Apr; 13 (4):e12440
    View PubMed
  3. Borgeaud M, Parikh K, Banna GL, Kim F, Olivier T, Le X, Addeo A. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review. J Thorac Oncol. 2024 Mar 16 [Epub ahead of print]
    View PubMed
  4. Nassar AH, El Zarif T, Khalid AB, Rahme S, Zhong C, Kwak L, Salame M, Farhat EB, Freeman D, El-Am E, Ravishankar A, Ahmad B, Nana FA, Kaldas D, Naqash AR, Sharon E, LeBoeuf NR, Cortellini A, Malgeri A, Gupta S, Al-Hader A, Sparks JA, Linnoila J, Hamnvik OR, Mouhieddine TH, Marron T, Parikh K, McKay RR, Dilling T, Choueiri TK, Adib E, Najem E, Kim SY, Sonpavde G. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. J Immunother Cancer. 2024 Mar 5; 12 (3) Epub 2024 Mar 05
    View PubMed
  5. Friedlaender A, Perol M, Banna GL, Parikh K, Addeo A. Oncogenic alterations in advanced NSCLC: a molecular super-highway. Biomark Res. 2024 Feb 12; 12 (1):24
    View PubMed
  6. Nassar AH, El-Am E, Denu R, Abou Alaiwi S, El Zarif T, Macaron W, Abdel-Wahab N, Desai A, Smith C, Parikh K, Abbasi M, Bou Farhat E, Williams JM, Collins JD, Al-Hader A, McKay RR, Malvar C, Sabra M, Zhong C, El Alam R, Chehab O, Lima J, Phan M, Dalla Pria HF, Trevino A, Neilan TG, Kwan JM, Ravi V, Deshpande H, Demetri G, Choueiri TK, Naqash AR. Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study. JACC CardioOncol. 2024 Feb; 6 (1):71-79 Epub 2024 Jan 16
    View PubMed
  7. Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer. Clin Lung Cancer. 2023 Dec; 24 (8):689-695.e1 Epub 2023 Sept 17
    View PubMed
  8. Imbimbo M, Wetterwald L, Friedlaender A, Parikh K, Addeo A. Cellular Therapy in NSCLC: Between Myth and Reality. Curr Oncol Rep. 2023 Oct; 25 (10):1161-1174 Epub 2023 Aug 30
    View PubMed
  9. Parekh J, Parikh K, Reuss JE, Friedlaender A, Addeo A. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer. Curr Oncol Rep. 2023 Aug; 25 (8):913-922 Epub 2023 May 30
    View PubMed
  10. Parikh K, Banna G, Liu SV, Friedlaender A, Desai A, Subbiah V, Addeo A. Drugging KRAS: current perspectives and state-of-art review. J Hematol Oncol. 2022 Oct 25; 15 (1):152
    View PubMed
  11. Giunta EF, Signori A, West HJ, Metro G, Friedlaender A, Parikh K, Banna GL, Addeo A. Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer. Front Oncol. 2022; 12:921854 Epub 2022 June 14
    View PubMed
  12. Parikh K, Hendriks LEL, Bironzo P, Remon J. Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges. Cancer Treat Rev. 2021 Sep; 99:102250 Epub 2021 June 16
    View PubMed
  13. Asmann YW, Parikh K, Bergsagel PL, Dong H, Adjei AA, Borad MJ, Mansfield AS. Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. NPJ Precis Oncol. 2021 Mar 19; 5 (1):22
    View PubMed
  14. Uprety D, Parikh K, Sawkar A, Dimou A, Leventakos K. Changing paradigm in advanced and metastatic non-small cell lung cancer. J Thorac Dis. 2020 Nov; 12 (11):6992-7001
    View PubMed
  15. Parikh K, Mandrekar SJ, Allen-Ziegler K, Esplin B, Tan AD, Marchello B, Adjei AA, Molina JR. A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). Oncologist. 2020 Jun; 25 (6):523-531 Epub 2019 Dec 24
    View PubMed
  16. Madhira BR, Konala VM, Adapa S, Naramala S, Ravella PM, Parikh K, Gentile TC. Recent Advances in the Management of Smoldering Multiple Myeloma. World J Oncol. 2020 Apr; 11 (2):45-54 Epub 2020 Mar 29
    View PubMed
  17. Parikh K, Huether R, White K, Hoskinson D, Beaubier N, Dong H, Adjei AA, Mansfield AS. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. JAMA Netw Open. 2020 Feb 5; 3 (2):e200202 Epub 2020 Feb 05
    View PubMed
  18. Ram P, Tiu A, Lo KB, Parikh K, Shah M. Trends in the prevalence of malignancy among patients admitted with acute heart failure and associated outcomes: a nationwide population-based study. Heart Fail Rev. 2019 Nov; 24 (6):989-995
    View PubMed
  19. Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current Diagnosis and Management of Small-Cell Lung Cancer. Mayo Clin Proc. 2019 Aug; 94 (8):1599-1622
    View PubMed
  20. Brumbaugh AD, Narurkar R, Parikh K, Fanucchi M, Frishman WH. Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy. Cardiol Rev. 2019 Mar/Apr; 27 (2):97-107
    View PubMed
  21. Liu D, Mehta D, Kaur S, Kumar A, Parikh K, Chawla L, Patel S, Devi A, Saha A. Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective. J Hematol Oncol. 2018 Dec 13; 11 (1):138
    View PubMed
  22. Parikh K, Kumar A, Ahmed J, Anwar A, Puccio C, Chun H, Fanucchi M, Lim SH. Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer. Cancer Immunol Immunother. 2018 Sep; 67 (9):1365-1370 Epub 2018 July 02
    View PubMed
  23. Shah M, Parikh K, Patel B, Agarwal M, Garg L, Agrawal S, Arora S, Patel N, Patel N, Frishman WH. Use of therapeutic hypothermia among patients with coagulation disorders - A Nationwide analysis. Resuscitation. 2018 Mar; 124:35-42 Epub 2018 Jan 03
    View PubMed
  24. Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, Chun H, Fanucchi M, Lim SH. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018; 7 (11):e1507670 Epub 2018 Aug 20
    View PubMed
  25. Parikh K, Shah M, Mehta D, Arora S, Patel N, Liu D. Increased Mortality Among Patients With Acute Leukemia Admitted on Weekends Compared to Weekdays. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17 (12):e33-e43 Epub 2017 Aug 09
    View PubMed
  26. Das A, Wei G, Parikh K, Liu D. Selective inhibitors of nuclear export (SINE) in hematological malignancies. Exp Hematol Oncol. 2015; 4:7 Epub 2015 Mar 01
    View PubMed
  27. Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol. 2014 Oct 15; 7:78
    View PubMed
  28. Gupta T, Parikh K, Puri S, Agrawal S, Agrawal N, Sharma D, DeLorenzo L. The forgotten disease: Bilateral lemierre's disease with mycotic aneurysm of the vertebral artery. Am J Case Rep. 2014; 15:230-4 Epub 2014 May 25
    View PubMed
  29. Thakar K, Parikh K, Chen Y, Liu D. Isolated factor V deficiency in a patient with elevated PT and aPTT during routine pre-operative laboratory screening. Stem Cell Investig. 2014; 1:4 Epub 2014 Feb 08
    View PubMed